Clinical Trial Update: Towards Personalized Dosing of Natalizumab in Multiple Sclerosis [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update exploring personalized dosing of natalizumab for multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Natalizumab (natalizumab)

Snippet

Sponsor: Amsterdam UMC, location VUmc | Conditions: Multiple Sclerosis | Phase 4 | Status: COMPLETED